Project Grant R01CA285959
Award Date
9/17/24
Completion Date
8/31/29
Dollars Obligated
$600K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,283,068 to The Washington University in St. Louis to develop and evaluate innovative, next-generation radioimmunotherapies for the treatment of non-Hodgkin lymphoma (NHL). The key objectives are: Assess novel anti-CD20 radioimmunotherapies using single-agent and combination therapies with beta-particle (Lu-177) and alpha-particle (Ac-225) emitters in preclinical NHL models to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The Trustees of the University of Pennsylvania to conduct early phase clinical trials of 211At-meta-astatobenzylguanidine (211At-MABG) for the treatment of neuroblastoma in children and advanced neuroendocrine cancers in adults. The total award amount is $695,205.00 over the project period from June 1, 2025 to May 31, 2030. The key objectives are to evaluate the safety and...
This $503,194 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at Seattle Children's Hospital aimed at developing an innovative multispecific T cell engager (MTE) therapy to treat neuroblastoma and other pediatric solid tumors. The key products and services being delivered under this 2-year award include: 1) Determining the efficacy of the R2P3 MTE, which binds to the ROR1 and PD-L1 tumor targets as well as CD3 on T cells,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $792,367 to Nanopharmaceuticals LLC to develop a novel dual-targeting ligand, NP855, for the treatment of high-risk neuroblastoma. The key products and services to be delivered under this grant include: Scaled-up manufacturing and analytical evaluation of the NP855 drug substance to enable formulation of the drug product. In vitro and in vivo studies to confirm the efficacy of the...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will provide $159,636 to the University of Wisconsin-Madison over 5 years starting August 1, 2024. The purpose of the award is to support the development of a translational research program led by Dr. Quaovi Sodji that investigates using low-dose targeted radionuclide therapy (TRT) to enhance the efficacy of chimeric antigen receptor (CAR) T cell therapy against neuroblastoma, a deadly...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,200,000 to Creative Biotherapeutics LLC, a biotechnology research firm, to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The project aims to target the extracellular glucose-regulated protein 78 (eGRP78), which is upregulated in drug-resistant recurrent brain cancers and promotes tumor growth, immune evasion, and stem cell formation. The...
This Project Grant award for $616,710.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Children's Research Institute in Washington, D.C. in designing effective adoptive immunotherapy for high-risk pediatric medulloblastoma. The research aims to develop a rational combination with MRI-guided focused ultrasound technology to enhance this innovative cancer treatment approach. The award period runs from August 1, 2024...
This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,905,304.00 over a five-year period from August 2024 to July 2029 to The Washington University in St. Louis to conduct research on an accelerated brachytherapy-forward chemoradiation therapy (ABC-RT) approach for the treatment of locally advanced cervical cancer. The key objectives are to: 1) Determine if the ABC-RT approach can safely shorten overall treatment time and maximize...